Announcement of The Consolidated Financial Report for The 2nd Quarter of 2026

2026.8.6

Provided by: TTY BIOPHARM COMPANY LIMITED

SEQ_NO	1	Date of announcement	2026/08/05	Time of announcement	17:17:17
Subject	Announcement of The Consolidated Financial Report for The 2nd Quarter of 2026
Date of events	2026/08/05	To which item it meets	paragraph 31
Statement	1.Date of the board of directors submitted or approved:2026/08/05 2.Date of the audit committee approved:2026/08/05 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2026/01/01~2026/06/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):3,172,151 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,881,379 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):976,534 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,117,655 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):897,622 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):849,483 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):3.42 11.Total assets end of the period (thousand NTD):11,825,563 12.Total liabilities end of the period (thousand NTD):4,076,937 13.Equity attributable to owners of parent end of the period (thousand NTD):6,955,426 14.Any other matters that need to be specified:None.